A Relaxin receptor agonist drug (RRA01) for the acute heartfailure treatment is developed by the Sunny Pharmaceutical Company.It is a publicly traded company. The reduction of cardiovasculardeath (mortality) was used as the end point (results of theresearch) for this investigation. The null hypothesis is “there isno difference in the cardiovascular mortality reduction betweenpatients who received RRA01 (treatment group) and those who did notreceive RRA01 (control group). Discuss the impact (on the companyand/or on the patients) of the following two possible clinicaltrial results to the Sunny Pharmaceutical Company, staff of thecompany, and the patients. 1. p = 0.002 as the hypothesis testresults 2. p = 0.3 as the hypothesis test results.
